Indeed, E is a TLR2 ligand for SARS-CoV-2 that can induce pro-inflammatory cytokines often associated with severe COVID-1958, hence the potential of anti-E antibodies blocking that interaction in children should be further investigated and potentially considered as a therapeutic tool in severe COVID-19. The gene discussed is TLR2; the disease is COVID-19.